CJC-1295 no DAC + Ipamorelin Blend
Peptide blend for research on the GH/IGF-1 axis, pulsatile growth hormone secretion, metabolism, and GHRH–ghrelin interactions.
What is CJC-1295 no DAC + Ipamorelin Blend
CJC-1295 no DAC + Ipamorelin Blend is a combination of two synthetic peptides studied in preclinical research for the modulation of growth hormone secretion and for the analysis of endocrine mechanisms linked to the GH/IGF-1 axis.
The blend combines CJC-1295 no DAC, also known as Mod GRF 1-29, an analog of Growth Hormone Releasing Hormone, and Ipamorelin, a selective pentapeptide belonging to the class of growth hormone secretagogues. The two compounds act through different receptors but converge on the same research area: the controlled and pulsatile stimulation of GH release.
This combination is of particular interest in experimental models studying endocrine physiology, metabolism, muscle function, bone metabolism, tissue regeneration, and the interaction between GHRH signaling and ghrelin receptors.
Role of CJC-1295 no DAC in endocrine studies
CJC-1295 no DAC, or Mod GRF 1-29, is a synthetic GHRH analog developed to replicate and enhance the biological activity of the active fragment of the natural hormone. Research on this peptide stems from the observation that the first 29 amino acids of GHRH are responsible for its main biological function.
Compared with the original GRF 1-29, Mod GRF 1-29 has structural modifications designed to increase enzymatic stability and prolong its duration of action, while maintaining its ability to bind to the GHRH receptor. In experimental systems, this allows for more reliable analysis of the stimulation of pituitary somatotroph cells and pulsatile growth hormone release.
Through activation of GHRH receptors, CJC-1295 no DAC is studied for its role in regulating the GH/IGF-1 axis, with interest in metabolism, cellular growth, tissue regeneration, muscle function, bone health, and controlled endocrine responses.
Role of Ipamorelin in studies on GH secretagogues
Ipamorelin is a synthetic pentapeptide derived from GHRP-1 and belonging to the class of growth hormone secretagogues. In experimental models, it is studied for its ability to selectively bind to the ghrelin receptor, also known as GHS-R1a.
Interest in Ipamorelin derives from its receptor selectivity. Preclinical and in vitro studies describe it as a compound capable of stimulating pulsatile GH release without significantly altering other endocrine axes, such as ACTH, prolactin, FSH, LH, TSH, or cortisol.
For this reason, Ipamorelin is used as a research model to study ghrelin receptor binding specificity, the physiology of GH secretion, growth and repair processes in musculoskeletal tissues, bone metabolism, and the interactions between GH, IGF-1, and metabolic regulation.
Why Study the CJC-1295 no DAC + Ipamorelin Blend
The scientific interest in the CJC-1295 no DAC + Ipamorelin Blend derives from the combination of two complementary mechanisms. CJC-1295 no DAC acts as a GHRH analog, stimulating the GHRH-R receptor, while Ipamorelin acts as a selective agonist of the ghrelin receptor GHS-R1a.
In experimental models, this dual interaction allows the response of the GH axis to be observed through two distinct but converging biological pathways. On one hand, GHRH signaling supports the physiology of pulsatile release; on the other, ghrelinergic signaling allows GH secretion to be analyzed through a separate and highly selective pathway.
This combination is therefore studied to better understand endocrine regulation of GH, IGF-1 production, metabolic response, the behavior of muscle and bone tissues, modulation of body composition in experimental models, and interactions between hypothalamic, pituitary, and peripheral signals.
Applications in experimental studies
In laboratory settings, CJC-1295 no DAC + Ipamorelin Blend is used for studies on pulsatile growth hormone secretion, regulation of the GH/IGF-1 axis, somatotroph cell response, selectivity of GHRH and GHS-R1a receptors, and communication between the endocrine system and peripheral tissues.
The most relevant research areas include muscle metabolism, bone metabolism, glucose homeostasis, tissue regeneration, glucocorticoid response, cardiovascular function, neuroendocrine tissues, and experimental models evaluating the relationship between GH, IGF-1, ghrelin, and energy regulation.
The observed results always depend on the model used, the experimental design, the concentration of the compound, the duration of exposure, and the selected analytical parameters. The blend should therefore be interpreted as a research tool for analyzing complex endocrine pathways, not as a product intended for clinical applications.
Reviews
There are no reviews yet.